Atai Beckley N.V. (NASDAQ:ATAI) has been added to the NASDAQ Biotechnology Index. On December 23, Chief Executive Officer Srinivas Rao stated that the company has made significant progress in its pipeline development and corporate foundation.
The index inclusion came after the company strengthened its balance sheet by raising $300 million in capital. This funding is expected to support moving multiple clinical programs into late-stage development.
Atai Beckley has also entered a strategic partnership with Beckley Psytech, deepening its leadership in developing next-generation mental health therapeutics.
"As we look ahead, AtaiBeckley is entering a pivotal phase and is well positioned to translate scientific leadership into long-term value for both patients and shareholders, as our recent addition to the NBI further validates," said Srinivas Rao, Chief Executive Officer of AtaiBeckley.
The company has completed the redomiciliation of its parent company, AtaiBeckley Group, from a Netherlands company to a U.S. entity. This move is expected to save costs, simplify the corporate structure, and streamline reporting requirements.
Atai Beckley N.V. is a clinical-stage biopharmaceutical company focused on treatments for mental health disorders. Its pipeline includes psychedelic and non-psychedelic compounds targeting conditions like depression and anxiety.